Sugi Predict

Sugi Predict / Compounds / SCHEMBL6689179

SCHEMBL6689179

SCHEMBL6689179

CN(C)c1ccc(-c2nnc(-c3ccccc3)o2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 1/20 0.71
▸ NPC1 O15118 16/20 0.71
▸ RAB9A P51151 15/20 0.71
▸ KMT2A Q03164 3/20 0.71
▸ RXFP1 Q9HBX9 2/20 0.69
▸ HPGD P15428 7/20 0.67
▸ ALDH1A1 P00352 6/20 0.67
▸ KDM4E B2RXH2 4/20 0.67
▸ MAPT P10636 3/20 0.67
▸ HSD17B10 Q99714 2/20 0.67
▸ SMN1; SMN2 Q16637 7/20 0.65
▸ NFKB1 P19838 2/20 0.64
▸ NFKB2 Q00653 2/20 0.64
▸ RELA Q04206 2/20 0.64
▸ MEN1 O00255 2/20 0.64
▸ HCRTR1 O43613 1/20 0.64
▸ GAA P10253 1/20 0.64
▸ CASP3 P42574 1/20 0.64
▸ SENP7 Q9BQF6 1/20 0.64
▸ POLB P06746 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL122784 0.92 APP (0.81) APPNPC1RAB9AKMT2ARXFP1
SCHEMBL8889974 0.90 APP (0.79) APPNPC1RAB9AKMT2ARXFP1
SCHEMBL556200 0.89 NPC1 (0.67) APPNPC1RAB9AKMT2ARXFP1
SCHEMBL3943643 0.85 APP (0.58) APPNPC1RAB9AKMT2ARXFP1
Styrene SCHEMBL3943655 0.85 APP (0.58) APPNPC1RAB9AKMT2ARXFP1
SCHEMBL12641772 0.85 APP (0.71) APPNPC1RAB9AKMT2ARXFP1
SCHEMBL4343181 0.83 NPC1 (0.94) NPC1RAB9AKMT2AHPGDALDH1A1
SCHEMBL1423326 0.83 NPC1 (1.00) APPNPC1RAB9AKMT2ARXFP1
SCHEMBL12573308 0.83 APP (1.00) APPNPC1RAB9AKMT2ARXFP1
SCHEMBL4871397 0.83 KDM4E (0.69) APPNPC1RAB9AKMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312491-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-10-05 — — US claimed
EP-4251614-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2023-10-04 — — EP claimed
CN-116457353-A N-substituted 4- (5-phenyl-1, 3, 4-oxadiazol-2-yl) anilines for the treatment and prophylaxis of hepatitis b virus infections 豪夫迈·罗氏有限公司 2023-07-18 — — CN claimed
WO-2022112139-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2022-06-02 — — WO claimed
US-20230312491-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-10-05 — — US disclosed
US-20230312491-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-10-05 — — US disclosed
US-20230312491-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-10-05 — — US disclosed
EP-4251614-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2023-10-04 — — EP disclosed
CN-116457353-A N-substituted 4- (5-phenyl-1, 3, 4-oxadiazol-2-yl) anilines for the treatment and prophylaxis of hepatitis b virus infections 豪夫迈·罗氏有限公司 2023-07-18 — — CN disclosed
WO-2022112139-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2022-06-02 — — WO disclosed
WO-2022112139-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2022-06-02 — — WO disclosed
US-9034655-B2 Highly water-soluble, cationic luminescent labels SETA BIOMEDICALS, LLC (US) 2015-05-19 — — US disclosed
US-9034655-B2 Highly water-soluble, cationic luminescent labels SETA BIOMEDICALS, LLC (US) 2015-05-19 — — US disclosed
US-20110143387-A1 HIGHLY WATER-SOLUBLE, CATIONIC LUMINESCENT LABELS SETA BIOMEDICALS, LLC 2011-06-16 — — US disclosed
US-20110143387-A1 HIGHLY WATER-SOLUBLE, CATIONIC LUMINESCENT LABELS SETA BIOMEDICALS, LLC 2011-06-16 — — US disclosed
US-20040248950-A1 Apo ai expression accelerating agent SHIONOGI & CO., LTD. (JP) 2004-12-09 — — US disclosed
EP-1419770-A1 APO AI EXPRESSION ACCELERATING AGENT SHIONOGI & CO., LTD. (JP) 2004-05-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248950-A1 Apo ai expression accelerating agent APOB, APOL1, NR1H2 APP 854/4885NPC1 129/4885RAB9A 3759/4885
US-20110143387-A1 HIGHLY WATER-SOLUBLE, CATIONIC LUMINESCENT LABELS SLC7A5, ABCG2, SLC43A1 APP 2674/4885NPC1 1507/4885RAB9A 354/4885
US-20230312491-A1 N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION SLC10A1, HAVCR2, CYP4B1 APP 4243/4885NPC1 106/4885RAB9A 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.